Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Extension Study to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of AT1001 in Patients With Fabry Disease

NCT00526071 is registered in ClinicalTrials.gov with Amicus Therapeutics as lead sponsor.

NCT NCT00526071
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00526071 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Extension Study to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of AT1001 in Patients With Fabry Disease
Lead sponsor
Amicus Therapeutics
Phase
Phase 2
Overall status
Terminated
Start date
September 17, 2007
Completion date
September 8, 2012
Enrollment
23 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

fabry disease